Exemestane - National Cancer Institute - aromasin for breast cancer treatment

Category

aromasin for breast cancer treatment - Side effects of exemestane (Aromasin) | Breast Cancer Care


AROMASIN is used in women who are past menopause for the treatment of: Early breast cancer (cancer that has not spread outside the breast) in women who: Advanced breast cancer (cancer that has spread) after treatment with tamoxifen, and it did not work or is no longer working. Mar 09, 2019 · Aromasin. postmenopausal women diagnosed with advanced-stage or metastatic hormone-receptor-positive breast cancer Women stop taking tamoxifen when they start taking Aromasin. Aromatase inhibitors can't stop the ovaries from making estrogen, so aromatase inhibitors are mainly used to treat postmenopausal women.

Sep 01, 2016 · Uses: Aromasin, used to treat postmenopausal women, typically is used to: reduce the risk of early-stage, hormone-receptor-positive breast cancer coming back after surgery and other treatments. treat advanced-stage, hormone-receptor-positive breast cancer. Aug 30, 2018 · Aromasin (exemestane) lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body. Aromasin is used to treat breast cancer in postmenopausal women. It is often given to women whose cancer has progressed even after surgery, radiation, 5/10.

Jun 11, 2018 · Aromasin (exemestane) is an antineoplastic (anticancer) agent used to treat breast cancer in postmenopausal women. Aromasin is often given to women whose cancer has progressed even after taking tamoxifen (Nolvadex, Soltamox) for 2 to 3 years. The drug is commercialized under the brand name Aromasin by Pfizer, and is used as an adjuvant treatment in postmenopausal women who suffer from estrogen receptor positive early-stage breast cancer. Women generally begin taking exemestane after they’ve been on tamoxifen for two to three years, then switch to exemestane for two to three years, for a total of five consecutive years of adjuvant hormonal therapy.